BNP Paribas Financial Markets
ACOR

BNP Paribas Financial Markets’s Acorda Therapeutics ACOR Stock Holding History

BNP Paribas Financial Markets’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30
Closed -$181 – 4856
2022
Q3 		$181 Buy
+30
New +$251 ﹤0.01% 4618
2020
Q4 		– Sell
-65
Closed -$4.01K – 4242
2020
Q3 		$4.01K Sell
65
-955
-94% -$72K ﹤0.01% 4027
2020
Q2 		$89.9K Buy
1,020
+859
+534% +$90.8K ﹤0.01% 2810
2020
Q1 		$18K Sell
161
-10
-6% -$1.97K ﹤0.01% 3929
2019
Q4 		$41.7K Buy
171
+103
+151% +$26K ﹤0.01% 3732
2019
Q3 		$23.5K Buy
68
+18
+36% +$9.79K ﹤0.01% 3881
2019
Q2 		$46K Sell
50
-35
-41% -$43K ﹤0.01% 3472
2019
Q1 		$136K Buy
85
+76
+844% +$137K ﹤0.01% 2938
2018
Q4 		$16.5K Sell
9
-125
-93% -$272K ﹤0.01% 3164
2018
Q3 		$316K Buy
134
+114
+570% +$353K ﹤0.01% 2216
2018
Q2 		$68.4K Sell
20
-100
-83% -$306K ﹤0.01% 2982
2018
Q1 		$341K Sell
120
-34
-22% -$102K ﹤0.01% 2463
2017
Q4 		$398K Sell
154
-45
-23% -$128K ﹤0.01% 2603
2017
Q3 		$565K Buy
199
+82
+70% +$216K ﹤0.01% 1919
2017
Q2 		$277K Buy
117
+39
+50% +$77.3K ﹤0.01% 2243
2017
Q1 		$197K Sell
78
-5
-6% -$14.4K ﹤0.01% 2218
2016
Q4 		$188K Buy
83
+26
+46% +$61.8K ﹤0.01% 2240
2016
Q3 		$142K Sell
57
-62
-52% -$185K ﹤0.01% 1923
2016
Q2 		$364K Buy
119
+64
+116% +$208K ﹤0.01% 1661
2016
Q1 		$173K Sell
55
-18
-25% -$74.7K ﹤0.01% 1592
2015
Q4 		$376K Sell
73
-1
-1% -$4.37K ﹤0.01% 1528
2015
Q3 		$236K Buy
74
+44
+147% +$171K ﹤0.01% 1839
2015
Q2 		$119K Buy
30
+22
+275% +$85K ﹤0.01% 1991
2015
Q1 		$32.9K Buy
+8
New +$36.6K ﹤0.01% 2133
2014
Q4 		– Sell
-21
Closed -$85.2K – 3396
2014
Q3 		$85.2K Buy
21
+20
+2,000% +$75K ﹤0.01% 2285
2014
Q2 		$5.8K Hold
1
– – ﹤0.01% 2514
2014
Q1 		$3.23K Sell
1
-3
-75% -$12.1K ﹤0.01% 2525
2013
Q4 		$15.4K Sell
4
-89
-96% -$347K ﹤0.01% 2376
2013
Q3 		$383K Sell
93
-25
-21% -$108K ﹤0.01% 1744
2013
Q2 		$468K Buy
+118
New +$486K ﹤0.01% 1610

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
SC
Saltoro Capital Dallas, Texas $30K AUM 24.79% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BNP Paribas Financial Markets's ACOR Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of Acorda Therapeutics (ACOR) in Q4 2022, closing a stake of 30 shares — an estimated $181 sold.

BNP Paribas Financial Markets first reported a position in ACOR in Q2 2013 and held it in 30 quarters. The position peaked at $565K in Q3 2017. 34 funds tracked by Wall St. Rank hold ACOR as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining Acorda Therapeutics position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 30 Acorda Therapeutics shares in Q4 2022, an estimated $181.
  • BNP Paribas Financial Markets first reported a position in Acorda Therapeutics in Q2 2013 and held it in 30 quarters.
  • BNP Paribas Financial Markets's Acorda Therapeutics position peaked at $565K in Q3 2017.
  • 34 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.